These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19951839)

  • 1. 3D QSAR studies on 3,4-dihydroquinazolines as T-type calcium channel blocker by comparative molecular similarity indices analysis (CoMSIA).
    Jeong JA; Cho H; Jung SY; Kang HB; Park JY; Kim J; Choo DJ; Lee JY
    Bioorg Med Chem Lett; 2010 Jan; 20(1):38-41. PubMed ID: 19951839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
    Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
    Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and SAR study of T-type calcium channel blockers. Part II.
    Choe YJ; Seo HN; Jung SY; Rhim H; Kim J; Choo DJ; Lee JY
    Arch Pharm (Weinheim); 2008 Oct; 341(10):661-4. PubMed ID: 18816587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives.
    Jo MN; Seo HJ; Kim Y; Seo SH; Rhim H; Cho YS; Cha JH; Koh HY; Choo H; Pae AN
    Bioorg Med Chem; 2007 Jan; 15(1):365-73. PubMed ID: 17035033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-type Ca2+ channel blockers suppress the growth of human cancer cells.
    Heo JH; Seo HN; Choe YJ; Kim S; Oh CR; Kim YD; Rhim H; Choo DJ; Kim J; Lee JY
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3899-901. PubMed ID: 18585035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent T-type calcium channel blocker.
    Seo HN; Choi JY; Choe YJ; Kim Y; Rhim H; Lee SH; Kim J; Joo DJ; Lee JY
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5740-3. PubMed ID: 17869104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and SAR studies of a novel series of T-type calcium channel blockers.
    Park SJ; Park SJ; Lee MJ; Rhim H; Kim Y; Lee JH; Chung BY; Lee JY
    Bioorg Med Chem; 2006 May; 14(10):3502-11. PubMed ID: 16434203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological activity of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers.
    Rhim H; Lee YS; Park SJ; Chung BY; Lee JY
    Bioorg Med Chem Lett; 2005 Jan; 15(2):283-6. PubMed ID: 15603940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore-based 3D-QSAR of HIF-1 inhibitors.
    Chung JY; Pasha FA; Cho SJ; Won M; Lee JJ; Lee K
    Arch Pharm Res; 2009 Mar; 32(3):317-23. PubMed ID: 19387572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of 3D-QSAR CoMSIA models for 5-(biphenyl-2-yl)-1H-tetrazole derivatives as angiotensin II receptor type 1 (AT1) antagonists.
    Choi MJ; Kwon GH; Han NS; Yoo BW; Kim JH; Paik SH; Chi YH; Lee KT; Lee JY
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4540-6. PubMed ID: 23845221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards predictive inhibitor design for the EGFR autophosphorylation activity.
    San Juan AA
    Eur J Med Chem; 2008 Apr; 43(4):781-91. PubMed ID: 17689836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First pharmacophoric hypothesis for T-type calcium channel blockers.
    Doddareddy MR; Jung HK; Lee JY; Lee YS; Cho YS; Koh HY; Pae AN
    Bioorg Med Chem; 2004 Apr; 12(7):1605-11. PubMed ID: 15028253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
    Puntambekar DS; Giridhar R; Yadav MR
    Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
    Bhongade BA; Gadad AK
    Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore-based alignment.
    Lu XY; Chen YD; You QD
    Chem Biol Drug Des; 2010 Feb; 75(2):195-203. PubMed ID: 20028393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers.
    Lee YS; Lee BH; Park SJ; Kang SB; Rhim H; Park JY; Lee JH; Jeong SW; Lee JY
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3379-84. PubMed ID: 15177437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.